What They Found: CytoDyn reviewed data from p
Post# of 154629
(Total Views: 550)
Posted On: 05/13/2025 9:07:42 AM
What They Found:
CytoDyn reviewed data from past mTNBC patients treated with leronlimab.
88% (15 out of 17) of those who received 525mg or more per week had a marked increase in PD-L1 — a key protein on their circulating tumor cells (CTCs).
This matters because PD-L1 expression is required for many patients to benefit from checkpoint inhibitor drugs (like Keytruda).
???? What This Means:
PD-L1 is like a molecular “flag” that makes tumors visible to the immune system — high PD-L1 = better chance ICIs will work.
Most triple-negative breast cancers are “cold,” meaning they don’t show this flag, so ICIs usually don’t work.
But leronlimab induced PD-L1 in these patients — potentially converting cold tumors into hot tumors.
???? Real-World Results:
Of the 5 patients who:
Took leronlimab,
Showed increased PD-L1,
And were later treated with any immune checkpoint inhibitor (ICI)…
???? All 5 are still alive.
4 are cancer-free (No Evidence of Disease).
The 5th is stable (tumor not growing).
This is remarkable given these were heavily pretreated, late-stage patients who had failed multiple other therapies.
???? Why This Is Big:
If confirmed in future trials, this could be a new, general mechanism for using leronlimab to help many kinds of cancers — not just TNBC.
Particularly helpful for patients with low PD-L1, who don’t qualify for existing ICI treatments.
CytoDyn is now actively collecting PD-L1 data in its colorectal cancer trial, aiming to extend this discovery to other solid tumors.
????⚕️ What CytoDyn Leadership Said:
Dr. Pestell: Leronlimab may unlock immunotherapy for patients with aggressive cancers who previously had no options.
Dr. Lalezari (CEO): If confirmed, this is a “game changer” — making ICI treatment possible for cold tumors using leronlimab first.
???? In Summary:
CytoDyn believes leronlimab may prime tumors to respond to existing immunotherapy by inducing PD-L1 expression, offering new hope to cancer patients previously ineligible for cutting-edge treatments.
CytoDyn reviewed data from past mTNBC patients treated with leronlimab.
88% (15 out of 17) of those who received 525mg or more per week had a marked increase in PD-L1 — a key protein on their circulating tumor cells (CTCs).
This matters because PD-L1 expression is required for many patients to benefit from checkpoint inhibitor drugs (like Keytruda).
???? What This Means:
PD-L1 is like a molecular “flag” that makes tumors visible to the immune system — high PD-L1 = better chance ICIs will work.
Most triple-negative breast cancers are “cold,” meaning they don’t show this flag, so ICIs usually don’t work.
But leronlimab induced PD-L1 in these patients — potentially converting cold tumors into hot tumors.
???? Real-World Results:
Of the 5 patients who:
Took leronlimab,
Showed increased PD-L1,
And were later treated with any immune checkpoint inhibitor (ICI)…
???? All 5 are still alive.
4 are cancer-free (No Evidence of Disease).
The 5th is stable (tumor not growing).
This is remarkable given these were heavily pretreated, late-stage patients who had failed multiple other therapies.
???? Why This Is Big:
If confirmed in future trials, this could be a new, general mechanism for using leronlimab to help many kinds of cancers — not just TNBC.
Particularly helpful for patients with low PD-L1, who don’t qualify for existing ICI treatments.
CytoDyn is now actively collecting PD-L1 data in its colorectal cancer trial, aiming to extend this discovery to other solid tumors.
????⚕️ What CytoDyn Leadership Said:
Dr. Pestell: Leronlimab may unlock immunotherapy for patients with aggressive cancers who previously had no options.
Dr. Lalezari (CEO): If confirmed, this is a “game changer” — making ICI treatment possible for cold tumors using leronlimab first.
???? In Summary:
CytoDyn believes leronlimab may prime tumors to respond to existing immunotherapy by inducing PD-L1 expression, offering new hope to cancer patients previously ineligible for cutting-edge treatments.
(20)
(0)